Free shipping on all orders over $ 500


Cat. No. M1503
Panitumumab Structure


Size Price Availability
5mg USD 900  USD900 4-7 Days
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Panitumumab is a fully human IgG2 monoclonal antibody specific to the epidermal growth factor receptor (EGFR). Panitumumab works by binding to the extracellular domain of the EGFR preventing its activation. This results in halting of the cascade of intracellular signals dependent on this receptor. The pharmacokinetics (PK) of panitumumab shows the so-called target-mediated disposition behavior.

Product Citations
Chemical Information
Molecular Weight 144321.76
Formula C6398H9878N1694O2016S48
CAS Number 339177-26-3
Storage -80°C for long term
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Douillard JY, et al. N Engl J Med. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

[2] Wells A Messersmith, et al. Clin Cancer Res . Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?

Related EGFR/HER2 Products

Unecritinib is a potent EGFR tyrosine kinase inhibitor that inhibits ALK, ROS1, and MET and has anticancer activity. Unecritinib is indicated for use in studies of solid tumors and ALK-positive anaplastic large cell lymphoma.

Almonertinib mesylate

Almonertinib mesylate is an orally active, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR sensitization and T790M resistance mutations, and also shows strong inhibitory activity against T790M, T790M/L858R, and T790M/Del19, with IC50 of 0.37, 0.29, and 0.21 nM, respectively. The IC50 of T790M/Del19 was 0.37, 0.29 and 0.21 nM, respectively, but the inhibitory effect on wild-type was weaker, with an IC50 of 3.39 nM. It can be used in the research of non-small cell lung cancer.


MAPK-IN-2 is a potent MAPK inhibitor with antineoplastic activity.


EGFR-IN-81 is an EGFR inhibitor.


EGFR-IN-85 is an EGFR inhibitor.

Abmole Inhibitor Catalog

Keywords: Panitumumab, ABX-EGF supplier, EGFR/HER2, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.